Vitruvias Therapeutics

What Vitruvias Therapeutics does

Vitruvias Therapeutics Inc. is a privately held specialty pharmaceutical company founded in 2013 and headquartered in Auburn, Alabama. The company markets and distributes prescription generic pharmaceutical products within the United States and Puerto Rico, operating as a contracting and distribution partner rather than a manufacturer. Its commercial portfolio consists of five FDA-approved generic products: Aminocaproic Acid Tablets, Cyanocobalamin Injection, Propafenone Hydrochloride Extended-Release Capsules, Pramipexole Dihydrochloride Extended-Release Tablets, and Bupropion Hydrochloride Extended-Release Tablets (XL). The company also offers authorized generic services to branded pharmaceutical companies seeking to launch authorized generics as patents near expiration, leveraging the brand sponsor's NDA to accelerate market entry.

The company's core business model is a B2B distribution and partnership platform. Vitruvias targets non-U.S.-based generic drug developers and manufacturers seeking U.S. market access, providing regulatory, commercial, and distribution infrastructure that is described as more compact and cost-efficient than larger pharmaceutical distributors. It also targets branded pharmaceutical companies approaching the patent cliff with authorized generic strategies, addressing the pain point of generic erosion by enabling the brand sponsor to capture authorized generic profitability. Distribution is executed through authorized distributors of record rather than a captive sales force. The go-to-motion is relationship-led business development outreach supplemented by a basic company website, with no disclosed digital marketing, no consumer-facing channels, and no app or API products.

Vitruvias is a small organization with 9-10 employees and has raised approximately $12.25 million across two disclosed funding events, including an $11.5 million Series A in January 2018 led by JW Asset Management and Perceptive Advisors, both of which hold board seats alongside founder-CEO Carl Whatley. The leadership team draws heavily from Kowa Pharmaceuticals America and prior Whatley-founded ventures (ProEthic Laboratories, divested to Kowa in 2008; Midlothian Laboratories, divested to Hi-Tech Pharmacal). The company has no disclosed proprietary technology platform, no AI/ML capabilities, and operates entirely as a human-expertise-driven services and distribution business in the U.S. generic pharmaceutical value chain.

Name

Vitruvias Therapeutics

Legal name

Vitruvias Therapeutics Inc.

Website

https://vitruvias.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Vitruvias Therapeutics is a privately held specialty pharmaceutical company that contracts and distributes generic and authorized generic prescription drugs in the U.S. and Puerto Rico, serving international generic manufacturers and branded pharma companies with five FDA-approved products and a compact distribution platform.

Ownership category

akta.pro rank

Product category

Generic Pharmaceutical Distribution

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Generic pharmaceuticals
• Authorized generics
• Pharmaceutical distribution
• Specialty drug contracting
• Niche topical generics

Headquarters

HQ city

Montgomery

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Generic Drug Distribution: Revenue is generated through the distribution of generic pharmaceutical products within the United States and Puerto Rico. The company partners with non-U.S. based generic drug developers and manufacturers to bring their products to the U.S. market through a highly efficient, streamlined distribution model.
2. Authorized Generic Services: The company provides authorized generic strategy services to branded pharmaceutical companies with near-patent expiration products. They offer distribution services that allow brand sponsors to launch their own generics, potentially increasing profitability through greater access to coverage with less exposure to high rebates.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels2 records

Core offering

Vitruvias Therapeutics is a specialty pharmaceutical company that markets and distributes prescription generic drug products within the United States and Puerto Rico. The company partners with non-U.S. based generic drug developers and manufacturers to bring their products to the U.S. market through a streamlined distribution model, and it also provides authorized generic strategy and distribution services to branded pharmaceutical companies with products approaching patent expiration.

Product overview

Vitruvias Therapeutics is a specialty pharmaceutical company that markets and distributes prescription generic pharmaceutical products within the United States and Puerto Rico. The company's product portfolio consists of five generic drug products: Aminocaproic Acid Tablets, USP (500 mg and 1000 mg); Cyanocobalamin Injection, USP 1000 mcg/mL; Propafenone Hydrochloride Extended-Release Capsules, USP (225 mg, 325 mg, and 425 mg); Pramipexole Dihydrochloride Extended-Release Tablets (0.375 mg and 0.75 mg); and Bupropion Hydrochloride Extended-Release Tablets, USP XL (150 mg and 300 mg). The company also offers authorized generic drug services for branded pharmaceutical companies seeking to protect market share and increase profitability when patents expire.

Differentiator

Problem solved

Functional benefit

Products and services

• Aminocaproic Acid Tablets, USP
• Cyanocobalamin Injection, USP 1000 mcg / mL
• Propafenone Hydrochloride Extended-Release Capsules, USP
• Pramipexole Dihydrochloride Extended-Release Tablets
• Bupropion Hydrochloride Extended-Release Tablets, USP (XL)
• Authorized Generic Strategy and Distribution Services

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Global Partners (unspecified)coreChannel Partner/ Reseller/ DistributorVitruvias describes 'Valued global partners' as essential to their success and expansion. They offer strategic partners commitment of resources, integrity, and industry expertise to ensure successful development and distribution of vital drugs into the American market. Specific partner names are not disclosed on their website.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Lannett Company: U.S. specialty generic pharmaceutical developer and distributor with a similar mix of niche generics, many partnered from international manufacturers. Comparable in scale and distribution-led commercial model.
• Mayne Pharma: Specialty pharmaceutical company that develops, manufactures, and markets generic and branded prescription drugs — comparable focus on niche generics and authorized-generic arrangements.
• ANI Pharmaceuticals: Specialty generics pharmaceutical company that acquires, develops, and markets generic and branded prescription pharmaceuticals in the U.S. Closely comparable in size, specialty-generic focus, and distribution-led model.
• Alvogen: Privately-held specialty generics company with significant U.S. presence that partners with international manufacturers to commercialize niche generics — a close analogue to Vitruvias' go-to-market model.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with extensive U.S. distribution. Indirect competitor in the generic and authorized-generic markets where Vitruvias operates.
• Sandoz (Novartis): Global leader in off-patent medicines with a broad U.S. generic portfolio. Competes indirectly with Vitruvias in the niche and authorized-generic segments but at vastly greater scale.
• Amneal Pharmaceuticals: Much larger U.S. generics and specialty pharma company with a broad portfolio of generic and authorized generics. Operates in the same market segment but at significantly greater scale, including in authorized generics.
• Heritage Pharmaceuticals (now part of Apotex): U.S. generics business focused on affordable generic prescription products across multiple therapeutic categories — directly comparable in product mix and channel focus, though larger and more diversified.
• Padagis (formerly Perrigo Company): Specialty generics company with a broad portfolio of generic Rx products distributed across the U.S. — comparable product/category footprint though larger scale than Vitruvias.
• Endo Pharmaceuticals (authorized generics business): Operates a substantial authorized-generics franchise through its subsidiaries (e.g., Par Pharmaceutical) — a direct competitor for branded pharma seeking authorized-generic partners, though at much greater scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vitruvias Therapeutics